Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK556884PMID: 32401469
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1446321-46-5
Drug Levels and Effects
Summary of Use during Lactation
Voxelotor is an orally administered drug that binds to hemoglobin S, inhibiting polymerization. No information is available on the appearance of voxelotor in milk or on the safety of the drug in breastfed infants, but its low molecular weight of 337 Da indicates that it probably passes into milk. Because of the potential for serious adverse reactions in the infant, breastfeeding is currently not recommended during treatment and for at least 2 weeks after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Voxelotor
CAS Registry Number
1446321-46-5
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Sotorasib.[Drugs and Lactation Database (...]Review Sotorasib.. Drugs and Lactation Database (LactMed®). 2006
- Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.[Pharmacotherapy. 2020]Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.Han J, Saraf SL, Gordeuk VR. Pharmacotherapy. 2020 Jun; 40(6):525-534. Epub 2020 May 19.
- A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.[N Engl J Med. 2019]A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, et al. N Engl J Med. 2019 Aug 8; 381(6):509-519. Epub 2019 Jun 14.
- A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.[Blood. 2019]A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.Howard J, Hemmaway CJ, Telfer P, Layton DM, Porter J, Awogbade M, Mant T, Gretler DD, Dufu K, Hutchaleelaha A, et al. Blood. 2019 Apr 25; 133(17):1865-1875. Epub 2019 Jan 17.
- Review Nilotinib.[Drugs and Lactation Database (...]Review Nilotinib.. Drugs and Lactation Database (LactMed®). 2006
- Voxelotor - Drugs and Lactation Database (LactMed®)Voxelotor - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...